Axcella to Present New Data at the Annual 2018 AASLD Liver Meeting

Effective therapies for NAFLD require coordinated reprogramming of cellular physiology as multiple pathways drive liver injury and disease progression. The presentation and poster will show AXA1125, the company’s unique metabolic modulator composition, as a potential candidate to address the multifactorial dysregulation in NAFLD with the goal of safely reprogramming cellular metabolism to simultaneously target insulin resistance, inflammation, and fibrogenesis.

Additional details of the presentation are as follows:

Title: AXA1125, a Novel Composition of Amino Acids Reprograms the Multifactorial Pathophysiology in NAFLD

Presenter: Manu Chakravarthy, M.D., Ph.D., Senior Vice President, Clinical Development and Chief Medical Officer

Abstract: 0106

Session: Parallel 13: Novel Therapeutics for NASH

Location: Moscone Center, North and South Buildings, Room 24/25

Date/Time: Sunday, November 11 at 2:45 PM

About Axcella™ Health
Metabolic dysregulation is at the heart of many diseases and maintaining metabolic function is core to health. Axcella is designing and developing endogenous metabolic modulator compositions with the goal of addressing metabolic dysregulation by safely reprogramming metabolism to either treat complex diseases or maintain health. With our diverse and expanding platform, we are transforming traditional discovery and development of drugs and health products. Our platform has already produced a rich pipeline of product candidates in programs that include liver, muscle, and CNS. Axcella Health was founded by Flagship Pioneering. www.axcellahealth.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20181022005162/en/